AMR Therapeutics

in silico

Virtual screening to identify target compounds through both ligand-based and structure-based approaches

in vitro

Leveraging extensive clinical metadata to screen and evaluate compounds and discovering new agents effective against microbial infections.

in vivo

In vivo testing on selected preclinical models to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of repurposed compounds in a biological system. "From Molecule to Model – Validating with Life”

Developing novel antimicrobial drugs, by a rational approach taking into account the mechanisms of Antimicrobial drug Resistance by targeting the pathways or proteins. Generative AI models are developed taking into account comprehensive and unbiased data sets followed by in vitro and in vivo validation

Products

SC004+SCAB1
Oral formulation
(Fixed dose combination)